{
    "nctId": "NCT00424983",
    "briefTitle": "Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year",
    "officialTitle": "A Stratified, Randomized, Open-label, Multi-center Comparative 2-arm Trial of PK, PD, and Safety of Zoledronic Acid Infusions Administered Monthly vs. Every 3-month, in Multiple Myeloma Patients With Malignant Bone Lesions, and Breast Cancer Patients With Bone Metastasis, Who Have Received 9-12* Doses of Zoledronic Acid Over the Prior Year. (*Amendment 1 Changed the Required Doses to 9-20 But Due to FDA Guidelines, the Title Has Not Been Changed)",
    "overallStatus": "COMPLETED",
    "conditions": "Multiple Myeloma, Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 18,
    "primaryOutcomeMeasure": "Sequential plasmas concentrations of zoledronic acid collected at 13 study visits between visit 2 to visit 17",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female between 18-75 years of age\n* Multiple myeloma or breast cancer with bone involvement\n* Treatment with zoledronic acid for bone lesions between 10-15 months prior to entry into study with a total of 9-20 infusions received.\n\nExclusion Criteria:\n\n* Current active dental problems or recent (within 8 weeks) or planned dental or jaw surgery\n* Active or uncontrolled infection, liver, or renal disease\n* History of treatment with intravenous bisphosphonates\n* Diagnosis of metabolic bone disorders other than osteoporosis (e.g. Paget's disease)\n\nOther protocol-defined inclusion/exclusion criteria may apply.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}